Wednesday, October 24, 2012

Novartis files QVA149 in Europe

QVA149 an investigational inhaled, once-daily, fixed-dose combination of indacaterol (LABA)
maleate and glycopyrronium bromide (NVA237 - LAMA) haas been filed for marketing authorisation with the European Medicines Agency (EMA). The filing triggers a $5m milestone payment to Sosei